Meeting Banner
Abstract #4843

Diffusion Weighted MRI for Assessing Treatment Response in Myeloma Bone Disease

Christina Messiou1, David Collins1, Veronica Morgan1, Sharon Giles1, Catherine Parry-Jones1, Faith Davies2, Gareth Morgan3, Nandita deSouza1

1CRUK and EPSRC Cancer Imaging Centre, Department of Magnetic Resonace Imaging, Institute of Cancer Research/The Royal Marsden Hospital, Sutton, Surrey, United Kingdom; 2Molecular Target Treatment Team, Institute of Cancer Research/The Royal Marsden Hospital, Sutton, Surrey, United Kingdom; 3Leukaemia and Molecular Genetics Team, Institute of Cancer Research/The Royal Marsden Hospital, Sutton, Surrey, United Kingdom


There is growing interest in diffusion weighted (DW) MRI as a biomarker of treatment response in metastatic and myeloma bone disease. We performed an ROC analysis of normal vs myeloma involved marrow. Using an ADC threshold of 724 mm2s-1 x 10-6 the sensitivity and specificity for detecting myeloma marrow involvement are 90 and 70% respectively. This threshold was applied to a test case to produce segmented ADC maps which were used to predict treatment response.